News

HDA UK Media And Political Bulletin – 23 June 2017

Queen’s Speech 2017: ABPI analysis

ABPI, 21 June 2017

 

With the UK Government having announced that there will be no Queen’s Speech in 2018, this Queen’s Speech sets out the Government’s legislative agenda for the next two years. The main focus of the Queen’s Speech was on setting out the Bills that will be required by Brexit. Notably, a number of Conservative manifesto pledges were not included in the Speech including proposals on fox hunting, grammar schools and changes to the winter fuel allowance and pensions. Of relevance to the pharmaceutical pharmacy, the Patient Protection Bill aims to create an independent Health Service Safety Investigation Body to oversee the investigation of mistakes and ‘never events’ in the NHS. It is unclear how this may impact on medicines safety and regulation.

 

BREAKING: New pharmacy minister announced

Chemist & Druggist, Annabelle Collins, 22 June 2017

 

Steve Brine MP will replace David Mowat as Pharmacy Minister, the Department of Health has confirmed yesterday afternoon. He will replace David Mowat MP, who has remained as Pharmacy Minister since losing his seat in the general election earlier this month. In May 2015, Mr. Brine was appointed as parliamentary private secretary to Health Secretary Jeremy Hunt. He also served as an assistant government whip from July 17, 2016 until last week (June 14).

 

New paper shares insights for safer medicines delivery

P3 Pharmacy, 21 June 2017

 

With many pharmacies reporting an increase for medication delivery services, especially for older or more vulnerable patients, the community pharmacy Patient Safety Group has developed a detailed discussion paper looking at how delivering medicines to people’s homes can be made as safe as possible.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Queen’s Speech 2017: ABPI analysis

ABPI, 21 June 2017

 

The 2017 Queen’s Speech took place today [21 June] at the State Opening of Parliament. With the Government having announced that there will be no Queen’s Speech in 2018, this Queen’s Speech sets out the Government’s legislative agenda for the next two years.

 

​The main focus of the Queen’s Speech was on setting out the Bills that will be required by Brexit. Notably, a number of Conservative manifesto pledges were not included in the Speech including proposals on fox hunting, grammar schools and changes to the winter fuel allowance and pensions.

 

Here is a brief summary of the key Bills of relevance to the pharmaceutical industry:​

 

Repeal Bill          

 

This will repeal the 1972 European Communities Act and convert all EU law into UK law. This will ensure there is no regulatory ‘cliff edge’ when Britain leaves the EU. Controversially, this Bill will create ‘Henry VIII’ powers which allow Parliament temporary powers to amend EU law without a vote.

 

Customs Bill

 

Regardless of the agreement that the UK comes to with the EU over any transitional arrangements ahead of Britain leaving the customs union, this Bill will ‘ensure the UK has a standalone UK customs regime on exit.’

 

Trade Bill

 

This Bill ‘will put in place the essential and necessary legislative framework to allow the U.K. to operate its own independent trade policy upon exit from the European Union.’

 

Immigration Bill

 

This will allow for controls on the number of people coming to the UK from Europe. If this Bill were not introduced then the free movement of people would become part of UK law under the Repeal Bill. The Bill does not indicate how liberal any future immigration policy might be, but suggests that it will still allow the UK to attract ‘the brightest and the best’.

 

Data Protection Bill

 

This primarily impacts on social media platforms and security services. It also updates the powers and sanctions available to the information commissioner. It is unclear whether this will have any impact on health data.

 

Patient Protection Bill

 

This creates an independent Health Service Safety Investigation Body to oversee the investigation of mistakes and ‘never events’ in the NHS. It is unclear how this may impact on medicines safety and regulation.

 

The Queen’s Speech only ever gives an overview of the legislation that the Government intends to introduce over the course of a Parliament. As more detail emerges on what these Bills are likely to include and when they are likely to be introduced to Parliament, the ABPI will be working understand how they will impact on the pharmaceutical sector and how they can be influenced. ​​​

New paper shares insights for safer medicines delivery

P3 Pharmacy, 21 June 2017

 

With many pharmacies reporting an increase for medication delivery services, especially for older or more vulnerable patients, the community pharmacy Patient Safety Group has developed a detailed discussion paper looking at how delivering medicines to people’s homes can be made as safe as possible.

 

To inform the paper, two members of the Patient Safety Group shadowed their delivery drivers for a day to gain a better understanding of the potential risks that can arise to patients, their families and to delivery drivers themselves.

 

A new paper looks at home delivery

 

The insights gathered through this shadowing exercise have been used to create tools to help delivery drivers and pharmacy teams evaluate the safety of their medicines delivery services, improving this vital community pharmacy service.

 

The Patient Safety Group reports that many pharmacies are already embedding these insights in their daily practice by updating delivery processes and procedures. The Group encourages pharmacies who offer, or are planning to offer, medication delivery services to read through the insights and consider how their services compare with the Group’s findings.

 

José Moss, deputy superintendent at Boots UK, Patient Safety Group member and lead author of the discussion paper said: “Shadowing our delivery drivers was a thoroughly enlightening experience. We gained a true insight into the complex needs of some of our delivery patients and the unique challenges that our delivery drivers face in their day-to-day work.

 

“This paper comes at a time when many community pharmacy teams are building more robust policies and procedures into their pharmacy practice around safeguarding children and vulnerable adults, in line with the new quality criteria.

 

“We have found through our experiences that often the most vulnerable of our patients are those who are less mobile or who have substantially fewer social interactions due to being home-based. These are often the patients who receive their medications via a delivery service so we feel it is timely that we publish our insights into providing the safest possible service for these groups.”

HDA UK Media And Political Bulletin – 23 June 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?